Premier Physicians Weight Loss and Wellness

Center Information

Kate Brennan
Premier Physicians Weight Loss and Wellness
607 S. Decatur Blvd.
Las Vegas, NV 89107
USA
702-822-7400
www.wellnesslasvegas.com
View Map

Therapeutic Areas

Cardiology/Vascular Diseases
Dermatology
Devices
Endocrinology
Healthy Volunteers
Internal Medicine
Musculoskeletal
Obstetrics/Gynecology (Women’s Health)
Otolaryngology (Ear, Nose, Throat)
Pediatrics/Neonatology
Urology
Vaccines

Center Overview

We are Premier Physicians Weight Loss and Wellness. Our mission is to improve lifestyle through nutritional diet, behavioral modification, and the latest advances in medicine. Our board certified physicians and staff combine the most complete and proven weight loss techniques, medications, and nutritional science to lose weight and promote healthy, active living, and prevent disease.

We are a dedicated full time clinic and new research site located in Las Vegas, NV. Our site is compliant with Good Clinical Practice, ICH Guidelines, HIPPA Regulations and FDA Regulations. We see patients with multiple health concerns and treat a variety of comorbidities at our practice such as diabetes, hypertension, hypogonadism, erectile dysfunction, metabolic syndrome, obesity, morbid obesity and men’s and women’s health and wellness. Our physicians also treat a large cliental in anti-aging, hormone replacement, and aesthetics.

With successful clients and years of experience the professionals at Premier Physicians can help individuals achieve and maintain a healthy lifestyle. Let us be your partners in health.

Performance Metrics

ACRP Certifications

Clinical Research Experience

Our site is detail oriented, protocol specific and committed to the safety of our patient population. All of our staff members are GCP trained and our coordinators are IATA certified. Dr. Dana Trippi is a published research investigator (Moscati R, Trippi D, Bailey G, Krasnoff M: Documentation of Domestic Violence in the Emergency Department Record, Ann Emerg Med 1999:34 (4):S99) and is known in the medical community for her various speaking engagements. These engagements include the Western States Osteopathic Convention for the “Introduction to the New Obesity Algorithm and Management”, Eisai Pharmaceuticals Consulting and Promotion, Williams – Sonoma Corporate Weight Loss Challenge, Girls Scouts of America addressing how to brown bag a healthy school lunch, Touro University for “Managing Obesity in your Practice”, the YMCA, and the ASBP Western Regional Symposium guiding medical professionals in “Starting Up a Weight Loss Practice”.

Facility Description

Premier Physicians Weight Loss and Wellness is an outpatient facility located in Las Vegas, NV. Our office hours are Monday through Friday 8:00am to 6:00pm. Our facility offers a comfortable waiting area, 3 exam rooms. 1 triage room, a dedicated monitoring room, EKG machine, body composition bio-impedance scales, and indirect calorimetry. We are compliant with locked cabinets, refrigerated and frozen storage (with a -20 centigrade freezer), and temperature monitoring equipment. We are fully equip to draw lab work on site for a variety of testing. In our monitoring room, we have onsite record storage to meet sponsors requirements.

Investigator Experience



Dana Trippi, D.O – Principal Investigator

Dr. Dana Trippi is a diplomat and Board Certified by the American Board of Emergency Medicine and the American Society of Bariatric Physicians. She is also a member of the Obesity Action Coalition. She has been a guest speaker at the American Society of Bariatric Physicians Conference, the Western States Osteopathic Convention, Eisai Pharmaceuticals, Girl Scouts of America, Touro Medical School University, YMCA, and the ASBP Western Regional Symposium. Dr. Trippi has practiced in Las Vegas since 1998 and is committed to obesity management in Las Vegas.

Currently working as a Sub Investigator for studies regarding type 2 diabetes with individuals of high cardiovascular risk, treatment of adults with mild infections of diabetic foot ulcers and medications administered in adults with type 2 diabetes mellitus controlled on Metformin, Long term Outcomes Study to Assess the Statin Residual Risk Reduction with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia (STRENGTH), and Trial Comparing Cardiovascular Safety of Insulin Glargine in Subjects with Type 2 Diabetes at High Cardiovascular Events.

Frederick Herman, MD – Principal Investigator

Frederick Herman, is a passionate doctor who has thirty years of research experience which has made him an expert Allergist. He has conducted research on asthma, allergies, respiratory infections, immunotherapy and chemical sensitivity. He is particularly passionate about children's health, and for many years served on the board of the Ronald McDonald House as the Director of the Asthma Camp Programs. Dr. Herman also served as Medical Director with the City of Long Beach, where he managed programs to assist in the treatment of children with asthma, diabetes, and obesity. Dr. Herman has taken his clinical expertise to the Las Vegas area, where he has been practicing for the last several years.

Eb Maendel, PA-C – Sub Investigator

Eb Maendel, Physician Assistant has experience as a Sub Investigator in various Dermatological studies including Plaque Psoriasis, Acne Vulgaris, Atopic Dermatitis and more. As a member of Clark County Medical Society, Eb is certified in Osteopathic Medicine as well as Emergency Medicine and is currently credentialed for Emergency Medicine at top hospitals around the Las Vegas area./p>

Erik Evensen, D.O– Sub Investigator

Dr. Erik Evensen is board certified in Emergency Medicine and is a diplomate of the American Society of Bariatric Physicians. Dr. Evensen is passionate about treating the obesity epidemic and has a special interest in Men’s Health and Men’s Anti-aging. His background gives him an edge in treating a broad expanse of acute and chronic diseases.

Currently working as a Sub Investigator for studies regarding type 2 diabetes with individuals of high cardiovascular risk, treatment of adults with mild infections of diabetic foot ulcers and medications administered in adults with type 2 diabetes mellitus controlled on Metformin, Long term Outcomes Study to Assess the Statin Residual Risk Reduction with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia, and Trial Comparing Cardiovascular Safety of Insulin Glargine in Subjects with Type 2 Diabetes at High Cardiovascular Events.

Staff Expertise

Jonathan Tyler, PA-C

Jonathan Tyler is a physicians assistant in Emergency Medicine with Emcare and a Bariatric/Men’s Health Specialist for Premier Physicians. His background as an Emergency Technician, his ability to fluently speak Spanish and his volunteer work in community youth sports makes him an asset in working with diverse demographics and treating a broad range of acute and chronic ailments. Jonathan is a member of both the Washington State Academy of Physicians Assistants and the American Academy of Physicians Assistants.

Colleen Burke, Physician Assistant

Colleen Burke received her Masters in Physician Assistant Studies from Touro University, Nevada. She received her BS in Kinesiology and Sports Medicine from the University of Nevada, Las Vegas. Colleen has practiced in Primary Care and Internal Medicine, and currently works in Emergency Medicine, as well as working as a Bariatric Specialist for Premier Physicians. Colleen is an active member of the American Academy of Physicians Assistants.

Pamela Monteiro - Research Coordinator
Languages: English and Cape Veredean Creole/Portugues

2014 - An Open-label, Multi-center, Expanded Treatment Protocol for patients with Acromegaly Safety Monitoring Program for Treating Patients with SOM230 (Pasireotide) LAR who have need to receive Medical Therapy (ACCESS).

2014 - Two Treatment Approaches for Human Regular U-500 Insulin (Thrice-Daily Versus Twice-Daily) in subjects with Type 2 Diabetes Mellitus not achieving adequate Glycemic Control on high-dose U-100 Insulin therapy with or without oral agents: A Randomized, Open-Label, Parallel Clinical Trial.

2014 - A Double-blind, Randomized, Placebo-controlled, Multicenter Study assessing the impact of additional LDL-Cholesterol reduction on major Cardiovascular Events when Evolocumab (AMG 145) is used in combination with Statin Therapy in Patients with clinically evident Cardiovascular Disease.

2014 - Type 1 Diabetes trial evaluating the safety and efficacy of Hylenex Recombinant and a new formulation of Hylenex.

2013 - A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as add-on therapy to Metformin in patients with Type 2 Diabetes.

2013 - Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients with Type 2 Diabetes.

2013 - A Randomized, Multi-Center Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated With Standard of Care for Type 2 Diabetes.

2013 - A Double-Blind, Randomized, 52-week Study to evaluate the impact of LY2605541 versus Insulin Glargine for patients with Type 1 Diabetes Mellitus treated with preprandial Insulin Lispro.

2013 - A Double-Blind, Randomized, 26-week Study to evaluate the impact of LY2605541 versus Insulin Glargine for patients with Type 2 Diabetes Mellitus advanced to multiple injection bolus insulin with Insulin Lispro.

2013 - An Open-Label, Randomized, 78-Week Study to evaluate the Impact of LY2605541 versus Insulin Glargine for patients with Type 1 Diabetes Mellitus treated with preprandial Insulin Lispro.

2013 - A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus injected in the morning or evening in patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period.

2012 - 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus both plus mealtime insulin in patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period.

2012 - 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study comparing the Efficacy and Safety of a new formulation of Insulin Glargine and Lantus both in combination with oral antihyperglycemic drug(s) in patients with Type 2 Diabetes Mellitus with a 6-month Safety Extension Period.

Patient Demographics

We provide services to a diversified population of patients ranging from 16 years of age to 75.

  • 50% Caucasian
  • 20% Hispanic
  • 15% African American
  • 15% Other
  • 60% Female
  • 40% Male

Other Information

Alternative Contact: Kate Brennan, Assistant Research Manager
Phone: 702-822-7400
Email: Kate.premierphysicians@gmail.com